Safety profile for PEMAZYRE — 1 of 1

The safety profile of PEMAZYRE was investigated in the FIGHT–202 study

In FIGHT-202, the most common AR observed with PEMAZYRE was hyperphosphataemia1

  • The safety of PEMAZYRE was investigated in the FIGHT–202 study in previously treated patients with CCA (N=147)1,27
 eDetail.safety.modal1.trigger.iconAlt

Serious ARs

 eDetail.safety.modal2.trigger.iconAlt

Selected ARs

 eDetail.safety.modal3.trigger.iconAlt

Special Warnings and
Precautions for use



For further safety information, please refer to the PEMAZYRE Summary of Product Characteristics.1


Healthcare professionals are asked to report any suspected ARs via the Yellow Card Scheme. Visit www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.1 Adverse events should also be reported to Incyte immediately by phoning 0330-100-3677 (Great Britain) or 00-800-0002-7423 (United Kingdom [Northern Ireland]).

MOST COMMON ARs OBSERVED WITH
PEMAZYRE (>15%)1,27

Bar chart showing common ARs observed with PEMAZYRE

Patients (%)

Most common ARs (any grade)